Dicerna Pharmaceuticals Hits New 1-Year Low at $15.00 (DRNA)
Dicerna Pharmaceuticals (NASDAQ:DRNA)’s share price reached a new 52-week low during trading on Thursday , American Banking News reports. The stock traded as low as $15.00 and last traded at $15.09, with a volume of 73,628 shares trading hands. The stock had previously closed at $15.79.
A number of analysts have recently weighed in on DRNA shares. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Wednesday, May 14th. They now have a $44.00 price target on the stock, down previously from $53.00. Analysts at Leerink Swann cut their price target on shares of Dicerna Pharmaceuticals from $60.00 to $48.00 in a research note on Wednesday, May 14th. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $44.33.
The stock’s 50-day moving average is $18.20 and its 200-day moving average is $25.01. The company’s market cap is $268.0 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($1.02) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.52) by $0.50. On average, analysts predict that Dicerna Pharmaceuticals will post $-2.27 earnings per share for the current fiscal year.
Dicerna Pharmaceuticals, Inc is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.